FDA-nixed diabetes drug from Lilly, Boehringer could face rough path to stardom

Save

The FDA may not have been so keen on Boehringer Ingelheim and Eli Lilly's Type 2 diabetes drug Jardiance when it issued a complete response letter in March for problems at its future production site. That didn't stop its across-the-pond counterpart from green-lighting the drug Friday–and it won't keep it from cracking the blockbuster barrier, analysts say. But that doesn't mean getting there will be easy.